Overview
This legislation establishes Medicare coverage for blood-based early detection screening tests for Alzheimer's disease and related dementias, representing a significant expansion of Medicare's preventive and diagnostic services. The bill targets the pre-symptomatic and early-stage detection of Alzheimer's disease and related dementias, recognizing that early identification is critical to improving patient outcomes and enabling timely intervention. By integrating these screening tests into the Medicare benefit structure, the bill aims to make cutting-edge biomarker-based diagnostics accessible to the elderly population most at risk for these conditions. The legislation reflects a broader policy shift toward leveraging advances in blood-based biomarker technology — including amyloid and tau protein detection — to identify neurodegenerative disease before clinical symptoms manifest, potentially transforming the standard of care for millions of Medicare beneficiaries.
Key Points
- Establishes a new Medicare benefit category for Alzheimer's disease and related dementias early detection screening tests.
- Targets pre-symptomatic and early-stage detection to enable timely clinical intervention.
- Incorporates FDA regulatory clearance as a prerequisite for Medicare coverage eligibility.
- Effective January 1, 2028, providing a multi-year runway for regulatory and administrative preparation.
Core Provisions
The bill amends Section 1861 of the Social Security Act by adding a new subsection defining 'Alzheimer's disease and related dementias early detection screening tests' as tests furnished on or after January 1, 2028, to detect pre-symptomatic and early stages of Alzheimer's disease or related dementias [§2(a)(nnn)]. To qualify for Medicare coverage, a test must have received FDA clearance under section 510(k), classification under section 513(f)(2) (the de novo pathway), or approval under section 515 of the Federal Food, Drug, and Cosmetic Act, ensuring that only rigorously validated diagnostics are covered. The bill also amends Section 1833(h)(1)(A) of the Social Security Act to authorize payment for these newly defined screening tests under Medicare Part B [§2(b)], integrating them into the existing clinical laboratory fee schedule payment framework. The definition of covered tests is deliberately broad, encompassing genomic sequencing blood or blood product tests as well as a wide range of equivalent tests as determined by the Secretary of Health and Human Services. These equivalent tests include single-analyte tests, blood test analysis of cell-free nucleic acids, multiplex panel tests, whole genome sequencing, protein expression analysis, whole exome sequencing, whole transcriptome analysis, and medical imaging based on blood, blood products, tissue, urine, or other biospecimens [§2(a)(s)(2)(A-B)].
Key Points
- Amends Social Security Act §1861 to define and establish coverage for Alzheimer's early detection screening tests.
- Requires FDA clearance (510(k)), de novo classification (513(f)(2)), or premarket approval (515) as a coverage prerequisite.
- Amends Social Security Act §1833(h)(1)(A) to authorize Medicare payment for covered tests.
- Covers a broad spectrum of test modalities including single-analyte, multiplex panel, cell-free nucleic acid, whole genome, whole exome, whole transcriptome, protein expression, and biospecimen-based imaging tests.
- Grants the Secretary authority to determine additional equivalent tests beyond those explicitly enumerated.
- Coverage effective January 1, 2028.
Legal References
- Social Security Act §1861, 42 U.S.C. 1395x
- Social Security Act §1833(h)(1)(A), 42 U.S.C. 1395l(h)(1)(A)
- Federal Food, Drug, and Cosmetic Act §510(k), 21 U.S.C. 360(k)
- Federal Food, Drug, and Cosmetic Act §513(f)(2), 21 U.S.C. 360c(f)(2)
- Federal Food, Drug, and Cosmetic Act §515, 21 U.S.C. 360e
Implementation
The Secretary of Health and Human Services bears primary responsibility for implementing the coverage framework established by this bill. The Secretary's most consequential implementation role is the authority to determine which tests qualify as 'equivalent' to the explicitly enumerated categories, a discretionary function that will shape the practical scope of coverage. This determination authority requires the Secretary to develop administrative criteria and processes for evaluating novel test technologies as they emerge, likely through the Centers for Medicare and Medicaid Services (CMS) coverage determination process. Tests must independently satisfy FDA regulatory requirements before Medicare coverage can attach, meaning the FDA's clearance and approval timelines will directly affect when specific tests become reimbursable. The bill does not specify dedicated funding mechanisms, reporting requirements, or explicit enforcement provisions beyond the existing Medicare payment and compliance infrastructure. Payment for covered tests will flow through the existing clinical laboratory fee schedule framework under Section 1833(h)(1)(A), meaning CMS will need to establish or assign appropriate billing codes and payment rates for these tests prior to the January 1, 2028 effective date.
Legal References
- Social Security Act §1833(h)(1)(A), 42 U.S.C. 1395l(h)(1)(A)
- 42 C.F.R. Part 493 (Clinical Laboratory Improvement Amendments)
- 42 C.F.R. Part 410 (Medicare Part B Benefits)
Impact
The primary direct beneficiaries are Medicare enrollees — predominantly individuals aged 65 and older — who are at risk for or in the early stages of Alzheimer's disease and related dementias. This population stands to gain access to blood-based biomarker screening that has historically been unavailable or unaffordable outside of clinical trials or out-of-pocket payment. Early detection enables earlier access to disease-modifying therapies, clinical trial enrollment, care planning, and lifestyle interventions, all of which can meaningfully affect disease trajectory and quality of life. Healthcare providers, particularly primary care physicians and neurologists, will gain a reimbursable tool to incorporate into routine cognitive health assessments. Test developers and manufacturers of FDA-cleared blood-based dementia diagnostics will gain a substantial new market through Medicare reimbursement. The administrative burden on CMS is significant, as the agency must establish coverage criteria, payment rates, and billing infrastructure before the 2028 effective date. The cost implications for the Medicare program are not specified in the bill, but given the large at-risk population and the broad definition of covered tests, program expenditures could be substantial. No sunset provisions are included, making this a permanent expansion of the Medicare benefit.
Key Points
- Medicare beneficiaries aged 65 and older gain access to covered blood-based Alzheimer's screening.
- Early detection enables timely access to emerging disease-modifying therapies and care planning.
- Healthcare providers gain a reimbursable diagnostic tool for cognitive health assessment.
- Test manufacturers gain Medicare market access upon FDA clearance or approval.
- CMS faces significant administrative burden in establishing payment rates and billing codes before 2028.
- No sunset provision — the coverage expansion is permanent.
Legal Framework
The bill operates squarely within Congress's authority to define and expand the Medicare benefit under Title XVIII of the Social Security Act, a well-established exercise of the spending power under Article I of the Constitution. The statutory vehicle is an amendment to Section 1861 of the Social Security Act, which defines covered services under Medicare, and Section 1833(h)(1)(A), which governs payment for clinical laboratory services. The bill creates a dual regulatory dependency: Medicare coverage is conditioned on prior FDA authorization under the Federal Food, Drug, and Cosmetic Act, meaning the FDA's regulatory framework for in vitro diagnostics and medical devices directly governs which tests qualify. This linkage to FDA clearance pathways — 510(k) substantial equivalence, 513(f)(2) de novo classification, and 515 premarket approval — ensures that coverage is tied to established federal safety and efficacy standards. The bill does not contain explicit preemption provisions affecting state law, and it does not create new judicial review mechanisms beyond those already available under the Administrative Procedure Act for CMS coverage and payment determinations. The Secretary's broad discretion to identify 'equivalent' tests creates a significant area of administrative law, as coverage determinations for novel tests will be subject to APA notice-and-comment rulemaking or national coverage determination processes.
Legal References
- U.S. Const. art. I, §8 (Spending Power)
- Social Security Act Title XVIII, 42 U.S.C. 1395 et seq.
- Social Security Act §1861, 42 U.S.C. 1395x
- Social Security Act §1833(h)(1)(A), 42 U.S.C. 1395l(h)(1)(A)
- Federal Food, Drug, and Cosmetic Act §510(k), 21 U.S.C. 360(k)
- Federal Food, Drug, and Cosmetic Act §513(f)(2), 21 U.S.C. 360c(f)(2)
- Federal Food, Drug, and Cosmetic Act §515, 21 U.S.C. 360e
- Administrative Procedure Act, 5 U.S.C. 551 et seq.
Critical Issues
The most significant implementation challenge is the breadth of the Secretary's discretion to determine 'equivalent' tests. This open-ended authority creates substantial uncertainty for test developers, payers, and providers about which tests will ultimately qualify for coverage, and it invites litigation from manufacturers whose tests are excluded from coverage determinations. The wide variety of test modalities explicitly enumerated — ranging from single-analyte blood tests to whole genome sequencing and biospecimen-based imaging — raises questions about whether the coverage definition is sufficiently bounded to prevent coverage of tests with marginal clinical utility or insufficient validation. The cost implications for Medicare are a serious concern: if a large proportion of the Medicare population undergoes annual or periodic screening, program expenditures could be substantial, particularly given that payment rates for advanced molecular diagnostics are typically high. There is also a risk of overdiagnosis and associated harms, including patient anxiety, unnecessary follow-up testing, and premature or inappropriate treatment in the absence of proven clinical benefit for pre-symptomatic individuals. The dual FDA-CMS regulatory dependency, while providing a quality safeguard, also creates a potential bottleneck: FDA clearance does not guarantee that CMS will establish favorable payment rates or that tests will be operationally available to providers by the 2028 effective date. Critics may argue that coverage should be conditioned on demonstrated clinical utility — not merely FDA clearance — and that the bill's broad test definition could result in coverage of tests that detect biomarkers without established therapeutic implications. Finally, the absence of any utilization management, frequency limitations, or clinical criteria for test ordering creates a risk of inappropriate utilization that could drive costs without proportionate clinical benefit.
Key Points
- Secretary's broad 'equivalent test' determination authority creates legal uncertainty and litigation risk.
- Broad test modality definition risks covering tests with insufficient clinical utility validation.
- Significant and unquantified Medicare cost exposure given the large at-risk population and high test costs.
- Risk of overdiagnosis, patient harm, and unnecessary downstream testing in pre-symptomatic populations.
- FDA clearance alone does not ensure clinical utility — coverage criteria may be insufficiently rigorous.
- No utilization management, frequency limits, or clinical ordering criteria to constrain inappropriate use.
- Operational readiness risk: CMS must establish billing codes and payment rates before January 1, 2028.